MedCore Peptides Contact →
MedCore Multi-Strength Copper Peptide Profile

GHK-Cu 50 mg & 100 mg

One canonical GHK-Cu entity page for MedCore 50 mg and 100 mg presentations, combining standardized copper-tripeptide identity, limited human evidence and route-specific FDA safety context.

Human Evidence ↓View Presentations →
MedCore GHK-Cu 50 mg product presentation
MedCore GHK-Cu 100 mg product presentation
ONE COPPER-PEPTIDE ENTITY2 MedCore strengths50 mg + 100 mg
CompoundGHK-Cu
MedCore strengths50 mg / 100 mg
PubChem CID139035031
Molecular weight400.90 g/mol
Human evidenceLimited
Page reviewed2 Sep 2026

What is GHK-Cu?

PubChem lists GHK-Cu as copper tripeptide, CID 139035031, with molecular formula C14H21CuN6O4− and molecular weight about 400.90 g/mol. It is the copper complex of glycyl-L-histidyl-L-lysine.1

Human evidence is limited and depends strongly on formulation and route. A small published topical study after CO2 laser resurfacing enrolled 13 completing participants and found no statistically significant objective difference in erythema, wrinkles or overall skin quality between groups, although a questionnaire outcome differed.2

GHK-Cu Human Evidence & Route-Specific Safety Context

For GHK-Cu, route and formulation matter. Topical human research should not be used as evidence for an unspecified or injectable research presentation.

PubMed

A small topical human study produced mixed findings

A controlled study of topical copper tripeptide complex following CO2 laser resurfacing reported no statistically significant objective differences in earlier erythema resolution, wrinkles or overall skin quality, while a patient questionnaire showed a difference in perceived overall skin quality. Thirteen patients completed the study.2

What this establishesA small topical study exists, but it does not establish broad clinical efficacy and does not test the MedCore 50 mg or 100 mg research products.
PubChem

Standardized copper-tripeptide identity

PubChem identifies GHK-Cu as copper tripeptide CID 139035031, molecular formula C14H21CuN6O4− and molecular weight 400.90 g/mol.1

U.S. FDA

Injectable-route compounding concern

FDA states that compounded injectable GHK-Cu may pose immunogenicity risks related to aggregation and peptide impurities and that human data are limited for safety considerations.3

Evidence boundary: The MedCore page does not infer injectable safety from topical studies, does not state a route of administration unless verified by product documentation, and does not convert experimental findings into treatment claims.

Available MedCore GHK-Cu Presentations

Both strengths share one canonical GHK-Cu entity page while retaining linkable, strength-specific product sections.

MedCore GHK-Cu 50 mg research presentation
50 mg

MedCore GHK-Cu 50 mg

A MedCore GHK-Cu 50 mg research presentation on the canonical copper-tripeptide entity page.

CompoundGHK-CuStrength50 mgPortfolioCopper peptide researchWebsite purposeResearch information
MedCore GHK-Cu 100 mg research presentation
100 mg

MedCore GHK-Cu 100 mg

A separate MedCore GHK-Cu 100 mg research presentation with strength-specific product identification.

CompoundGHK-CuStrength100 mgPortfolioCopper peptide researchWebsite purposeResearch information
Variant policy: The strength variants share the same copper-tripeptide evidence base; route, formulation and analytical details remain product-documentation questions rather than inferred facts.

Quality & Documentation

Product documentation should specify what is actually verified for each MedCore strength without extrapolating topical or injectable findings across routes.

  • Strength-specific product identification
  • Batch documentation when published
  • Analytical records when verified
  • Route claims only when documented
Explore MedCore Quality →
MC
MEDCORE PEPTIDESGHK-Cu profile
Canonical entityGHK-Cu
Presentation A50 mg
Presentation B100 mg
Identity sourcePubChem
Evidence sourcesPubMed / FDA
No route, purity, batch or laboratory result is asserted here without product-specific documentation.

COA / Laboratory Documentation

Strength-specific documentation preview for the MedCore GHK-Cu research presentation.

Sample COA / laboratory documentation for MedCore GHK-Cu 50 mg
GHK-Cu 50 mgSample documentation for presentation purposes; not independently verified.
Sample COA / laboratory documentation for MedCore GHK-Cu 100 mg
GHK-Cu 100 mgSample documentation for presentation purposes; not independently verified.
Documentation note

These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.

Related MedCore Research Profiles

Related pages build topical connections while keeping route and evidence limitations explicit.

Peptide researchBPC-157Explore profile →Peptide researchCJC-1295 DACExplore profile →Metabolic researchSemaglutideExplore profile →

GHK-Cu Questions & Answers

Answers deliberately distinguish identity, topical human evidence, route-specific FDA context and MedCore product information.

GHK-Cu is a copper tripeptide complex. PubChem lists it as CID 139035031.1
Yes, but the human evidence base is limited. One small topical study after CO2 laser resurfacing reported mixed findings and only 13 participants completed the study.2
FDA states that compounded injectable GHK-Cu may pose immunogenicity risk related to aggregation and peptide impurities and that human safety data are limited.3
No. Route, formulation and product-specific analytical information should only be stated when verified in MedCore documentation.
They are strength variants of the same GHK-Cu entity, so one canonical page avoids duplicating the same evidence and source material.
No. The website is an informational portfolio and documentation platform.

Authoritative Sources

The source layer deliberately distinguishes standardized identity, topical human research and FDA's injectable-route safety concern. Last reviewed 2 September 2026.

  1. 1
    PubChem: Copper tripeptide (GHK-Cu), CID 139035031

    Standardized GHK-Cu identity, formula and molecular weight.

    Open PubChem source ↗
  2. 2
    PubMed: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

    Small controlled human study illustrating the limited and route-specific clinical evidence base.

    Open PubMed source ↗
  3. 3
    U.S. FDA: Certain Bulk Drug Substances That May Present Significant Safety Risks

    FDA route-specific safety context for compounded injectable GHK-Cu.

    Open FDA source ↗
MEDCORE PEPTIDES

GHK-Cu evidence by route, with two MedCore strengths on one canonical entity page.

Review the quality framework or contact MedCore for product-specific documentation.

Quality & Documentation →Contact MedCore →
Research-use information: This page is informational and does not provide medical advice, dosing instructions, route-of-administration guidance or treatment claims.
\n
Review the evidence contextUse the MedCore methodology and disclaimer when interpreting product research and documentation.
\n
\n\n